• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

European Medicines Agency rejects breakthrough Alzheimer’s drug

Quote








Biogen Eisai Alzheimer's drug Leqembi rejected by European regulator

https://www.cnbc.com/amp/2024/07/26...g-leqembi-rejected-by-european-regulator.html

KEY POINTS
  • European drug regulators rejected the Alzheimer's treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S.
  • The European Commission, the EU's executive body, has a final say. But it almost always follows the drug regulator's recommendations.
  • The regulator said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine.
 




anonymous said:
Biogen Eisai Alzheimer's drug Leqembi rejected by European regulator

https://www.cnbc.com/amp/2024/07/26...g-leqembi-rejected-by-european-regulator.html

KEY POINTS
  • European drug regulators rejected the Alzheimer's treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S.
  • The European Commission, the EU's executive body, has a final say. But it almost always follows the drug regulator's recommendations.
  • The regulator said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine.
Click to expand...
Why would anyone work at this company? Jobs open all over the place? No credibility with doctors and poor leadership.
 
















Top Bottom
Back
Quote